Altered monocyte cyclo-oxygenase response in non-obese diabetic mice

• Published in: Clinical and experimental immunology Vol. 155; no. 2; pp. 304 - 310
• Main Authors: Beyan, H, Buckley, L.R, Bustin, S.A, Yousaf, N, Pozzilli, P, Leslie, R.D
• Format: Journal Article
• Language: English
• Published: Oxford, UK Oxford, UK : Blackwell Publishing Ltd 01.02.2009; Blackwell Publishing Ltd; Blackwell; Blackwell Science Inc
• Subjects: Analytical, structural and metabolic biochemistry; Animals; Autoimmunity; Biological and medical sciences; Cells, Cultured; Cyclooxygenase 1 - biosynthesis; Cyclooxygenase 1 - genetics; Cyclooxygenase 2 - biosynthesis; Cyclooxygenase 2 - genetics; Cyclooxygenase 2 Inhibitors - therapeutic use; diabetes; Diabetes Mellitus, Experimental - enzymology; Diabetes Mellitus, Experimental - pathology; Diabetes Mellitus, Experimental - prevention & control; Diabetes. Impaired glucose tolerance; Down-Regulation; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Female; Fundamental and applied biological sciences. Psychology; Gene Expression Regulation, Enzymologic; inflammation; Lactones - therapeutic use; Lipopolysaccharides - immunology; Medical sciences; Membrane Proteins - biosynthesis; Membrane Proteins - genetics; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Monocytes - enzymology; monocytes/macrophage; NOD mice; Prostaglandin-Endoperoxide Synthases - biosynthesis; Prostaglandin-Endoperoxide Synthases - genetics; Reverse Transcriptase Polymerase Chain Reaction - methods; RNA, Messenger - genetics; Sulfones - therapeutic use; Up-Regulation; Endocrinopathy; Autoimmunity; Animal model; Monocyte; Enzyme; Diabetes mellitus; Biochemistry; Inflammation; monocytes/macrophage; Oxygenase; Animal; Oxidoreductases; Non obese diabetic mouse; NOD mice; diabetes; Macrophage
• ISSN: 0009-9104; 1365-2249
• DOI: 10.1111/j.1365-2249.2008.03825.x

Monocytes infiltrate islets in non-obese diabetic (NOD) mice. Activated monocyte/macrophages express cyclo-oxygenase-2 (COX-2) promoting prostaglandin-E₂ (PGE₂) secretion, while COX-1 expression is constitutive. We investigated in female NOD mice: (i) natural history of monocyte COX expression basally and following lipopolysaccharide (LPS) stimulation; (ii) impact of COX-2 specific inhibitor (Vioxx) on PGE₂, insulitis and diabetes. CD11b⁺ monocytes were analysed for COX mRNA expression from NOD (n = 48) and C57BL/6 control (n = 18) mice. NOD mice were treated with either Vioxx (total dose 80mg/kg) (n = 29) or methylcellulose as control (n = 29) administered by gavage at 4 weeks until diabetes developed or age 30 weeks. In all groups, basal monocyte COX mRNA and PGE₂ secretion were normal, while following LPS, after 5 weeks of age monocyte/macrophage COX-1 mRNA decreased (P < 0·01) and COX-2 mRNA increased (P < 0·01). However, diabetic NOD mice had reduced COX mRNA response (P = 0·03). Vioxx administration influenced neither PGE₂, insulitis nor diabetes. We demonstrate an isoform switch in monocyte/macrophage COX mRNA expression following LPS, which is altered in diabetic NOD mice as in human diabetes. However, Vioxx failed to affect insulitis or diabetes. We conclude that monocyte responses are altered in diabetic NOD mice but COX-2 expression is unlikely to be critical to disease risk.